Predictive value of HBsAg quantification in pegylated interferon therapy for chronic hepatitis B
10.3969/j.issn.1001-5256.2016.05.041
- VernacularTitle:HBsAg定量检测对聚乙二醇干扰素治疗慢性乙型肝炎效果的预测价值
- Author:
Haiyue ZHANG
1
;
Pei ZHOU
;
Zuojiong GONG
Author Information
1. Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
hepatitis B;
surface antigens;
interferons;
forecasting;
review
- From:
Journal of Clinical Hepatology
2016;32(5):977-980
- CountryChina
- Language:Chinese
-
Abstract:
Antiviral therapy is the most important thing in the treatment of chronic hepatitis B (CHB). Pegylated interferon (PEG-IFN) has both antiviral and immunomodulatory effects, and after drug withdrawal, 30%-40% of patients can achieve HBeAg seroconversion and sustained virologic response. Many studies have shown that HBsAg quantification can be used as an index to predict the anti-HBV effect of PEG-IFN and sustained immune control after drug withdrawal. This article reviews the relationship between HBsAg levels before, during, and after PEG-IFN therapy and antiviral effect to clarify the significance of HBsAg quantification in the PEG-IFN treatment of CHB and to guide the regimen of antiviral therapy.
